- Home
- PAYO vs VERA Comparison
PAYO vs VERA Comparison
Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- VERA
- Stock Information
- Founded
- PAYO 2005
- VERA 2016
- Country
- PAYO United States
- VERA United States
- Employees
- PAYO N/A
- VERA N/A
- Industry
- PAYO EDP Services
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- VERA Health Care
- Exchange
- PAYO Nasdaq
- VERA Nasdaq
- Market Cap
- PAYO 2.5B
- VERA 2.0B
- IPO Year
- PAYO N/A
- VERA 2021
- Fundamental
- Price
- PAYO $6.84
- VERA $23.39
- Analyst Decision
- PAYO Strong Buy
- VERA Buy
- Analyst Count
- PAYO 8
- VERA 8
- Target Price
- PAYO $10.44
- VERA $64.63
- AVG Volume (30 Days)
- PAYO 2.6M
- VERA 3.0M
- Earning Date
- PAYO 08-06-2025
- VERA 08-07-2025
- Dividend Yield
- PAYO N/A
- VERA N/A
- EPS Growth
- PAYO N/A
- VERA N/A
- EPS
- PAYO 0.28
- VERA N/A
- Revenue
- PAYO $996,150,000.00
- VERA N/A
- Revenue This Year
- PAYO $4.32
- VERA N/A
- Revenue Next Year
- PAYO $5.59
- VERA N/A
- P/E Ratio
- PAYO $24.34
- VERA N/A
- Revenue Growth
- PAYO 14.86
- VERA N/A
- 52 Week Low
- PAYO $5.03
- VERA $18.53
- 52 Week High
- PAYO $11.29
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- PAYO 45.47
- VERA 49.48
- Support Level
- PAYO $6.73
- VERA $20.40
- Resistance Level
- PAYO $6.95
- VERA $25.30
- Average True Range (ATR)
- PAYO 0.18
- VERA 1.31
- MACD
- PAYO 0.01
- VERA -0.02
- Stochastic Oscillator
- PAYO 31.34
- VERA 46.25
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.